ArticleInternational journal of environmental research and public health2019
Pathologic Complete Response (pCR) and Survival of Women with Inflammatory Breast Cancer (IBC): An Analysis Based on Biologic Subtypes and Demographic Characteristics.
Article in International journal of environmental research and public health, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Systematic Review and Meta-Analysis of Treatment Effects on Survival in Patients with Inflammatory Breast Cancer.Asian Pacific journal of cancer prevention : APJCP · 2023Pooled it
- Retrospective review of metastatic hormone receptor-positive inflammatory breast cancer patients reveals poor responses to cyclin dependent kinase 4/6 inhibition.Breast cancer research : BCR · 2025Article
- Inhibition of DDX3 modulates immune signaling in aggressive breast cancers.Cancer letters · 2025Article
- miRNA and Its Implications in the Treatment Resistance in Breast Cancer-Narrative Review of What Do We Know So Far.Non-coding RNA · 2025Review
- Correlation of TROP2 expression with clinico-pathological features and outcomes in HR+/HER2- breast cancer receiving neoadjuvant chemotherapy.The oncologist · 2025Article
- Rates of Pathologic Complete Response and Overall Survival in Patients with Inflammatory Breast Cancer: A National Cancer Database Study.Annals of surgical oncology · 2024Article
- Improved Rate of Negative Margins for Inflammatory Breast Cancer Using Intraoperative Frozen Section Analysis.Cancers · 2023Article
- Clinical outcomes of de novo metastatic HER2-positive inflammatory breast cancer.NPJ breast cancer · 2023Article
- Article
- Characterization of Inflammatory Breast Cancer in Hispanic Women from Puerto Rico.Journal of Cancer · 2022Article
- Overview of MicroRNA Expression in Predicting Response to Neoadjuvant Therapies in Human Epidermal Growth Receptor-2 Enriched Breast Cancer - A Systematic Review.Breast cancer : basic and clinical research · 2022Review
- Early on-treatment transcriptional profiling as a tool for improving pathological response prediction in HER2-positive inflammatory breast cancer.Therapeutic advances in medical oncology · 2022Article
- Radiotherapy in the Management of Non-Metastatic Inflammatory Breast Cancers: A Retrospective Observational Study.Cancers · 2021Article
- Clinicopathological response to neoadjuvant therapies and pathological complete response as a biomarker of survival in human epidermal growth factor receptor-2 enriched breast cancer - A retrospective cohort study.Breast (Edinburgh, Scotland) · 2021Article
- Clinical endpoints in oncology - a primer.American journal of cancer research · 2021Review
- Survival Analysis of Patients with Inflammatory Breast Cancer in Relation to Clinical and Histopathological Characteristics.Cancer management and research · 2020Article
- The Efficacy of Pegylated Liposomal Doxorubicin-Based Neoadjuvant Chemotherapy in Breast Cancer: A Retrospective Case-Control Study in Taiwan.Biochemistry research international · 2020Article
- Pathologic complete response and overall survival in breast cancer subtypes in stage III inflammatory breast cancer.Breast cancer research and treatment · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this US-based study of the National Cancer Database (NCDB), we examined 8550 patients diagnosed with non-metastatic, invasive inflammatory breast cancer (IBC) who received surgery from 2004⁻2013. Patients were grouped into four biologic subtypes (HR⁺/HER
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.